Atea Pharmaceuticals Income Statement (2020-2022) | AVIR

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022
Revenue & cost
Revenue 65.98M60.39M32.81M192.18M
Operating items
Research & Development 2.82M13.60M13.85M26.57M39.80M43.02M57.81M29.63M19.86M4.91M27.54M
Selling, General & Administrative 1.22M4.03M14.14M8.76M11.90M11.94M13.19M12.54M12.44M11.38M12.36M
Operating Expenses 4.04M17.63M27.99M35.33M51.70M54.96M71.00M42.17M32.30M16.28M39.90M
Operating Income -4.04M-17.63M20.65M30.66M8.69M-22.15M121.18M-42.17M-32.30M-16.28M-39.90M
EBIT -4.04M-17.63M20.65M30.66M8.69M-22.15M121.18M-42.17M-32.30M-16.28M-39.90M
Non-operating items
Interest & Investment Income 0.06M0.01M0.01M0.06M0.05M0.05M0.05M0.10M1.08M4.38M5.59M
Net income details
EBT -3.99M-17.62M20.66M30.71M8.74M-22.09M121.23M-42.08M-31.21M-11.90M-34.31M
Tax Provisions 7.20M6.10M4.10M0.12M-3.83M0.12M
Profit After Tax -3.99M-17.62M20.66M30.71M1.54M-28.19M117.13M-42.08M-31.34M-8.07M-34.43M
Income from Continuing Operations -3.99M-17.62M20.66M30.71M1.54M-28.19M117.13M-42.08M-31.34M-8.07M-34.43M
Consolidated Net Income -3.99M-17.62M20.66M30.71M1.54M-28.19M117.13M-42.08M-31.34M-8.07M-34.43M
Income towards Parent Company -3.99M-17.62M20.66M30.71M1.54M-28.19M117.13M-42.08M-31.34M-8.07M-34.43M
Net Income towards Common Stockholders -3.99M-17.62M20.66M30.71M1.54M-28.19M117.13M-42.08M-31.34M-8.07M-34.43M
Additional items
EPS (Basic) -0.40-1.742.620.370.02-0.341.41-0.51-0.38-0.10-0.41
EPS (Weighted Average and Diluted) -0.40-1.742.620.340.02-0.341.32-0.51-0.38-0.10-0.41
Shares Outstanding (Weighted Average) 79.24M79.24M82.62M82.74M82.74M83.10M83.10M83.26M83.26M83.26M83.29M
EBITDA -4.04M-17.63M20.65M30.66M8.69M-28.19M117.13M-42.08M-31.34M-8.92M-34.26M
Shares Outstanding 10.09M10.11M10.11M82.44M82.74M82.78M83.05M83.10M83.26M83.26M83.29M
Tax Rate 82.393.3832.21